Sanford-Burnham team discovers new target for intestinal tumors; Microbiome study zeroes in on Type 1 diabetes;

> Researchers at Sanford-Burnham Medical Research Institute have pinpointed stem cell molecules that spur intestinal cancer, offering a new target for drug investigators. Release

> In what is billed as the "largest longitudinal study of the microbiome to date," researchers from the Broad Institute of MIT and Harvard, Massachusetts General Hospital and the DIABIMMUNE Study Group have identified a connection between changes in gut microbiota and the onset of Type 1 diabetes. Release

> A team at Scripps has been investigating the role immune "memory'" plays in the effectiveness of vaccine boosters, with an eye to improving on a new generation of jabs. "We can now see the evolution of better protection in single memory cells as they respond to the boost," said TSRI Professor Michael McHeyzer-Williams, senior author of the new study. Story

> Researchers at the University of Toronto found that Candida albicans--a leading cause of potentially fatal hospital-acquired infections--rarely develops resistance to combination drug therapy and, when it becomes resistant, it also becomes less dangerous. Release